Overview
XENE market data
Price History
XENE price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.36 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.56 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -867.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $35.60 – $72.66 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $6.2B · P/B 6.09 · P/S 827.84.
Company News
RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $81Benzinga · Aug 7, 2026, 8:27 PM
8-K filing — Xenon Pharmaceuticals Inc. (XENE)SEC EDGAR · Aug 6, 2026, 8:11 PM
Xenon Pharmaceuticals Q2 EPS $(1.11) Beats $(1.15) EstimateBenzinga · Aug 6, 2026, 8:02 PM
Analyst Warns Biohaven's Lead Drug May Struggle To Stand OutBenzinga · Jun 29, 2026, 6:10 PM
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsightGlobenewswire Inc · Jun 10, 2026, 5:15 PM
JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $82Benzinga · May 27, 2026, 1:55 PM